Refinement of the clinical and mutational spectrum of UBE2A deficiency syndrome.


Journal

Clinical genetics
ISSN: 1399-0004
Titre abrégé: Clin Genet
Pays: Denmark
ID NLM: 0253664

Informations de publication

Date de publication:
08 2020
Historique:
received: 15 04 2020
revised: 11 05 2020
accepted: 13 05 2020
pubmed: 18 5 2020
medline: 10 7 2021
entrez: 17 5 2020
Statut: ppublish

Résumé

UBE2A deficiency, that is, intellectual disability (ID) Nascimento type (MIM 300860), is an X-linked syndrome characterized by developmental delay, moderate to severe ID, seizures, dysmorphisms, skin anomalies, and urogenital malformations. Forty affected subjects have been reported thus far, with 31 cases having intragenic UBE2A variants. Here, we report on additional eight affected subjects from seven unrelated families who were found to be hemizygous for previously unreported UBE2A missense variants (p.Glu62Lys, p.Arg95Cys, p.Thr99Ala, and p.Arg135Trp) or small in-frame deletions (p.Val81_Ala83del, and p.Asp101del). A wide phenotypic spectrum was documented in these subjects, ranging from moderate ID associated with mild dysmorphisms to severe features including congenital heart defects (CHD), severe cognitive impairment, and pineal gland tumors. Four variants affected residues (Glu62, Arg95, Thr99 and Asp101) that contribute to stabilizing the structure of the E3 binding domain. The three-residue in-frame deletion, p.Val81_Ala83del, resulted from aberrant processing of the transcript. This variant and p.Arg135Trp mapped to regions of the protein located far from the E3 binding region, and caused variably accelerated protein degradation. By reviewing available clinical information, we revise the clinical and molecular profile of the disorder and document genotype-phenotype correlations. Pineal gland cysts/tumors, CHD and hypogammaglobulinemia emerge as recurrent features.

Identifiants

pubmed: 32415735
doi: 10.1111/cge.13775
doi:

Substances chimiques

UBE2A protein, human EC 2.3.2.23
Ubiquitin-Conjugating Enzymes EC 2.3.2.23

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

172-178

Informations de copyright

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002;82:373-428. https://doi.org/10.1152/physrev.00027.2001.
Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014;20(11):1242-1253.
Roest HP, Baarends WM, de Wit J, et al. The ubiquitin-conjugating DNA repair enzyme HR6A is a maternal factor essential for early embryonic development in mice. Mol Cell Biol. 2004;24(12):5485-5495.
Koken MH, Smit EM, Jaspers-Dekker I, et al. Localization of two human homologs, HHR6A and HHR6B, of the yeast DNA repair gene RAD6 to chromosomes Xq24-q25 and 5q23-q31. Genomics. 1992;12:447-453.
Nascimento RMP, Otto PA, de Brouwer APM, Vianna-Morgante AM. UBE2A, which encodes a ubiquitin-conjugating enzyme, is mutated in a novel X-linked mental retardation syndrome. Am J Hum Genet. 2006;79:549-555.
Czeschik JC, Bauer P, Buiting K, et al. X-linked intellectual disability type Nascimento is a clinically distinct, probably underdiagnosed entity. Orphanet J Rare Dis. 2013;8:146.
Haddad DM, Vilain S, Vos M, et al. Mutations in the intellectual disability gene UBE2A cause neuronal dysfunction and impair parkin-dependent mitophagy. Mol Cell. 2013;50(6):831-843.
Stevenson RE, Chudley AE, Srivastava AK, Rodriguez J, Friez MJ, Schwartz CE. UBE2A-related X-linked intellectual disability. Clin Dysmorphol. 2019;28(1):1-6.
Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36:928-930.
Firth HV, Richards SM, Bevan AP, et al. DECIPHER: database of chromosomal imbalance and phenotype in humans using Ensembl resources. Am J Hum Genet. 2009;84(4):524-533.
Budny B, Badura-Stronka M, Materna-Kiryluk A, et al. Novel missense mutations in the ubiquitination-related gene UBE2A cause a recognizable X-linked mental retardation syndrome. Clin Genet. 2010;77(6):541-551.
Hong JH, Kaustov L, Coyaud E, et al. KCMF1 (potassium channel modulatory factor 1) links RAD6 to UBR4 (ubiquitin N-recognin domain-containing E3 ligase and lysosome-mediated degradation). Mol Cell Proteomics. 2015;14:674-685.

Auteurs

Viviana Cordeddu (V)

National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.

Erica L Macke (EL)

Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Francesca Clementina Radio (FC)

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCSS, Rome, Italy.

Stefania Lo Cicero (S)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.

Francesca Pantaleoni (F)

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCSS, Rome, Italy.

Massimo Tatti (M)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.

Emanuele Bellacchio (E)

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCSS, Rome, Italy.

Andrea Ciolfi (A)

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCSS, Rome, Italy.

Emanuele Agolini (E)

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCSS, Rome, Italy.

Alessandro Bruselles (A)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.

Nicola Brunetti-Pierri (N)

Department of Translational Medicine, Federico II University of Naples, Naples, Italy.
Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.

Mohnish Suri (M)

Regional Clinical Genetics Service, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Katherine S Josephs (KS)

Medical Genetics, St George's University Hospitals, London, UK.

Meriel McEntagart (M)

Medical Genetics, St George's University Hospitals, London, UK.

Brendan Lanpher (B)

Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota, USA.

Katherine C Nickels (KC)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Andrea Haworth (A)

Congenica, Wellcome Genome Campus, Cambridge, UK.

Laura Reed (L)

Congenica, Wellcome Genome Campus, Cambridge, UK.

Gerarda Cappuccio (G)

Department of Translational Medicine, Federico II University of Naples, Naples, Italy.
Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.

Isabella Mammi (I)

AULSS3 Serenissima, Ospedale Dolo, Dolo, Italy.

Jessica M Tarnowski (JM)

Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota, USA.

Antonio Novelli (A)

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCSS, Rome, Italy.
Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.

Daniela Melis (D)

Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana", Università di Salerno, Salerno, Italy.

Bert Callewaert (B)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.

Bruno Dallapiccola (B)

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCSS, Rome, Italy.

Eric Klee (E)

Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota, USA.

Marco Tartaglia (M)

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCSS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH